MBM Commercial advises Wobble Genomics as it raises £8.5 million

MBM Commercial was delighted to represent Wobble Genomics, a groundbreaking company in the field of RNA sequencing, in its recent funding round of £8.5 million to further advance its pioneering technology.

This funding round, spearheaded by Mercia Ventures and BGF, and supported by IQ Capital, EOS Advisors, and Old College Capital (OCC), marks a significant milestone for Wobble Genomics, bringing the total amount raised by the company to over £10.5 million. MBM are proud to have played a part in facilitating this collaboration between Wobble Genomics and its investors.

“We are thrilled to witness the company's continued success in its mission to revolutionize various sectors within biotechnology. This recent investment is a great reflection of the promise in what the team are delivering and the appetite of investors to back the ambitions of the Wobble Genomics team”, noted Alexander Lamley, Corporate Partner at MBM Commercial.

Wobble Genomics has developed an innovative approach to RNA sequencing that has the potential to transform numerous fields within biotechnology. By detecting previously imperceptible 'full-length' RNA molecules, Wobble's technology opens doors to a wide array of applications, ranging from drug development and research to agriculture and ecology. This breakthrough underscores the importance of RNA sequencing in gaining insights into cellular behaviour and its implications for various industries.

MBM Commercial has provided legal advice to Wobble Genomics since its spinout from the University of Edinburgh in 2021. As Dr Nicola Broughton, Chair of Wobble Genomics, noted:

“We’ve used MBM Commercial for our legal advice for several years now, and Alex and the team have guided us through our investment rounds with multiple stakeholders with ease. MBM’s ability to advise on the US aspects of the recent deal and to support our US ambitions is also really helpful. We value their insight and responsiveness throughout the process.”

The company will use the new capital to further advance its RNA research and sequencing and expects to double the workforce in the next two years.

Founded in 2005, MBM Commercial is an award winning and entrepreneurial UK commercial law firm with offices in London and Edinburgh. The firm specializes in corporate transactions with a particular focus on M&A, investment, technology and scale-up, often involving US and other cross-jurisdictional issues.